Indomethacin-5-fluorouracil-methyl ester dry emulsion: A potential oral delivery system for 5-fluorouracil

Drug Development and Industrial Pharmacy

Volumn 36, Issue 6, 2010, Pages 647-656

  Wang, Jing ^a   Hu, Yanchen ^a   Li, Ling ^a   Jiang, Tongying ^a   Wang, Siling ^a   Mo, Fengkui ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

5 Fluorouracil; Dry emulsion; In situ perfusion experiment; Indomethacin; Indomethacin 5 fluorouracil methyl ester

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; INDOMETHACIN 5 FLUOROURACIL METHYL ESTER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; EMULSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; INCUBATION TIME; LIPOPHILICITY; MASS SPECTROMETRY; MELTING POINT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PARTICLE SIZE; PHYSICAL CHEMISTRY; RAT;

ADMINISTRATION, ORAL; ANIMALS; DRUG DELIVERY SYSTEMS; EMULSIONS; ESTERS; FLUOROURACIL; GASTROINTESTINAL TRACT; INDOMETHACIN; METHYLATION; RATS;

EID: 77952476943     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903410318     Document Type: Article

References (34)

1. Tebbutta NC, Cattellb E, Midgleyb R, Cunninghama D, Kerrb D. (2002). Systemic treatment of colorectal cancer. Eur J Cancer, 38:1000-15.
2. Fraile RJ, Baker LN, Buroker TR, Horwitz J, Vaitkevicius VK. (1980). Pharmacokinetics of 5-fluorouracil administered orally by rapid intravenous and by slow infusion. Cancer Res, 40:2223-8.
3. Meropol NJ. (1998). Oral fluoropyrimidines in the treatment of colorectal cancer. Eur J Cancer, 34:1509-13.
4. Phillips TA, Howell A, Grieve RJ, Welling PG. (1980). Pharmacokinetics of oral and intravenous 5-fluorouracil in humans. J Pharm Sci, 69:1428-31.
5. Saif MW, Syrigos KN, Katirtzoglou NA. (2009). S-1: A promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs, 18:335-48.
6. 3-O-toluyl-fluorouracil-loaded liposomes. Int J Pharm, 353:243-50.
7. Malet-Martino M, Martino R. (2002). Clinical studies of three oral prodrugs of 5-fluorouracil (Capecitabine, UFT, S-1): A review. Oncologist, 7:288-323.
8. Hull MA, Gardner SH, Hawcroft G. (2003). Activity of the nonsteroidal anti-inflammatory drug indomethacin against colorectal cancer. Cancer Treat Rev, 29:309-20.
9. Maca RD. (1991). Enhancement of etoposide and methotrexate sensitivity by indomethacin in vitro. Anticancer Drug Des, 6:453-66.
10. Ruegg C, Zaric J, Stupp R. (2003). Non steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-cancer therapeutics: Hypes, hopes and reality. Ann Med, 35:476-87.
11. Fujino H, Chen X, Regan JW, Murayama T. (2007). Indomethacin decreases EP2 prostanoid receptor expression in colon cancer cells. Biochem Biophys Res Commun, 359:568-73.
12. Kapitanović S, Čačev T, Antica M, Kralj M, Cavrić G, Pavelić K, et al. (2006). Effect of indomethacin on E-cadherin and β-catenin expression in HT-29 colon cancer cells. Exp Mol Pathol, 80:91-6.
13. Dahan A, Duvdevani R, Dvir E, Elmann A, Hoffman A. (2007). A novel mechanism for oral controlled release of drugs by continuous degradation of a phospholipid prodrug along the intestine: In-vivo and in-vitro evaluation of an indomethacin- lecithin conjugate. J Control Release, 119:86-93.
14. Mishra A, Veerasamy R, Jain PK, Dixit VK, Agrawal RK. (2008). Synthesis, characterization and pharmacological evaluation of amide prodrugs of ketorolac. Eur J Med Chem, 43:2464-72.
15. Christensen KL, Pedersen GP, Kristensen HG. (2001). Preparation of redispersible dry emulsions by spray drying. Int J Pharm, 212:187-94.
16. Dollo G, Corre PL, Guerina A, Chevannea F, Burgotb JL, Leverge R. (2003). Spray-dried redispersible oil-in-water emulsion to improve oral bioavailability of poorly soluble drugs. Eur J Pharm Sci, 19:273-80.
17. Hansen T, Holm P, Rohde M, Schultz K. (2005). In vivo evaluation of tablets and capsules containing spray-dried o/w-emulsions for oral delivery of poorly soluble drugs. Int J Pharm, 293:203-11.
18. Jang DJ, Jeong EJ, Lee HM, Kim BC, Lim SJ, Kim CK. (2006). Improvement of bioavailability and photostability of amlodipine using redispersible dry emulsion. Eur J Pharm Sci, 28:405-11.
19. Wang G, Wang J, Qi. W, Chen Y, Sun L. (2008). Determination of indomethacin 5-fluorouracil-1-methyl ester and its related substances by RP-HPLC. Shenyang Yao Ke Da Xue Xue Bao, 25:563-6.
20. Leo A, Hansch C, Elkins D. (1971). Partition coefficients and their uses. Chem Rev, 71:525-616.
21. Liao ZG, Ping QN, Xiao W, Liang XL. (2005). The Study in situ on rat intestinal absorption of the active components in Guizhifuling capsule. Chin J Nat Med, 3:303-7.
22. Stella VJ, Nti-Addae KW. (2007). Prodrug strategies to overcome poor water solubility. Adv Drug Deliv Rev, 59:677-94.
23. Kalgutkar AS, Marnett AB, Crews BC, Remmel RP, Marnett LJ. (2000). Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors. J Med Chem, 43:2860-70.
24. Buur A, Trier L, Magnusson C, Artursson P. (1996). Permeability of 5-fluorouracil and prodrugs in Caco-2 cell monolayers. Int J Pharm, 129:223-31.
25. McLeod AD, Friend DR, Tozer TN. (1993). Synthesis and chemical stability of glucocorticoid-dextran esters: Potential prodrugs for colon-specific delivery. Int J Pharm, 92:105-14.
26. Wu H, Lu C, Zhou A, Min Z, Zhang Y. (2009). Enhanced oral bioavailability of puerarin using microemulsion vehicle. Drug Dev Ind Pharm, 35:138-44.
27. Dahan A, Hoffman A. (2008). Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J Control Release, 129:1-10.
28. Pouton CW, Porter CJH. (2008). Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies. Adv Drug Deliv Rev, 60:625-37.
29. Chambin O, Berard V, Rochat-Gonthier MH, Pourcelot Y. (2002). Dry adsorbed emulsion: 2. Dissolution behaviour of an intricate formulation. Int J Pharm, 235:169-78.
30. Porter CJH, Wasan KM, Constantinides P. (2008). Lipid-based systems for the enhanced delivery of poorly water soluble drugs. Adv Drug Deliv Rev, 60:615-6.
31. Smith P, Mirabelli C, Fondacaro J, Ryan F, Dent J. (1988). Intestinal 5-fluorouracil absorption: Use of Ussing chambers to assess transport and metabolism. Pharm Res, 5:598-603.
32. Stewart BH, Chan OH, Jezyk N, Fleisher D. (1997). Discrimination between drug candidates using models for evaluation of intestinal absorption. Adv Drug Deliv Rev, 23:27-45.
33. Kent TH, Cardelli RM, Stamler FW. (1969). Small intestinal ulcers and intestinal flora in rats given indomethacin. Am J Pathol, 54:237-49.
34. Chandrasekaran S, Al-Ghananeem AM, Riggs RM, Crooks PA. (2006). Synthesis and stability of two indomethacin prodrugs. Bioorg Med Chem, 16:1874-9.